Document Detail


Use of sympathetic alpha antagonists in the management of pediatric urologic disorders.
MedLine Citation:
PMID:  16770128     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: To update the physician regarding the use of alpha-adrenergic antagonists in the management of various pediatric urologic problems. RECENT FINDINGS: The use of alpha-adrenergic antagonist for the treatment of pediatric urologic disorders has expanded greatly over the past decade. This review summarizes the current use of these medications in the treatment of pediatric voiding dysfunction, neurogenic bladder, chronic lower urinary tract symptomatology, idiopathic urethritis, and the passage of ureteral calculi. SUMMARY: Currently alpha antagonist therapy although not useful in the primary treatment of voiding dysfunction is equivalent in potency to biofeedback therapy for the treatment of recalcitrant voiding dysfunction. In the management of neurogenic bladder and chronic lower urinary tract symptomatology, alpha antagonists working alone or in conjunction with anticholinergic medications will improve clinical symptoms, increase bladder compliance, and decrease detrusor instability. In addition, alpha antagonists may decrease the intensity and duration of symptoms in patients with idiopathic urethritis. Compared with placebo, alpha-adrenergic antagonists will also aid significantly in the spontaneous passage of distal ureteral calculi, thereby reducing the need for surgical intervention and analgesia. The findings noted above significantly expand the clinical usefulness of alpha antagonist therapy within the field of pediatric urology.
Authors:
Douglas A Husmann
Related Documents :
22237768 - Vitamin d status and cytokine levels in patients with crohn’s disease.
24560868 - The tumor necrosis factor family member tnfsf14 (light) is required for resolution of i...
2533328 - Intracerebroventricular administration of beta-endorphin releases immunoreactive met-en...
11268338 - Contribution of differently localized alpha 2- and beta-adrenoceptors in the modulation...
12668258 - Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mic...
21859968 - Role of complement component c1q in the onset of preeclampsia in mice.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in urology     Volume:  16     ISSN:  0963-0643     ISO Abbreviation:  Curr Opin Urol     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-13     Completed Date:  2006-11-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9200621     Medline TA:  Curr Opin Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  277-82     Citation Subset:  IM    
Affiliation:
Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA. dhusmann@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use*
Animals
Child
Chronic Disease
Dose-Response Relationship, Drug
Humans
Nervous System Diseases / drug therapy
Receptors, Adrenergic, alpha / metabolism
Urologic Diseases / drug therapy*,  metabolism,  physiopathology
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Receptors, Adrenergic, alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ambiguous genitalia.
Next Document:  The role of magnetic resonance imaging in pediatric urology.